Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (thrombin) and factor Xa.
=== In medicine and medical research === Purified lectins are important in a clinical setting because they are used for blood typing. Some of the glycolipids and glycoproteins on an individual's red blood cells can be identified by lectins.
== See also == Aptamers, oligonucleotides with important biological applications Morpholinos, oligos with non-natural backbones, which do not activate RNase-H but can reduce gene expression or modify RNA splicing Polymorphism, the appearance in a population of the same gene in multiple forms because of mutations; can often be tested with ASO probes CpG Oligodeoxynucleotide, an ODN with immunostimulatory properties Polypurine reverse-Hoogsteen hairpins, PPRHs, oligonucleotides that can bind either DNA or RNA and decrease gene expression.
=== Formation of the T-pilus === To transfer T-DNA into a plant cell, A. tumefaciens uses a type IV secretion mechanism, involving the production of a T-pilus. When acetosyringone and other substances are detected, a signal transduction event activates the expression of 11 genes within the VirB operon which are responsible for the formation of the T-pilus. The pro-pilin is formed first. This is a polypeptide of 121 amino acids which requires processing by the removal of 47 residues to form a T-pilus subunit. The subunit was thought to be circularized by the formation of a peptide bond between the two ends of the polypeptide. However, high-resolution structure of the T-pilus revealed no cyclization of the pilin, with the overall organization of the pilin subunits being highly similar to those of other conjugative pili, such as F-pilus. Products of the other VirB genes are used to transfer the subunits across the plasma membrane. Yeast two-hybrid studies provide evidence that VirB6, VirB7, VirB8, VirB9 and VirB10 may all encode components of the transporter. An ATPase for the active transport of the subunits would also be required.
== Signals and noise == One of the most important components of analytical chemistry is maximizing the desired signal while minimizing the associated noise. The analytical figure of merit is known as the signal-to-noise ratio (S/N or SNR). Noise can arise from environmental factors as well as from fundamental physical processes.
Sources: en.wikipedia.org
== Nobel Prize == In 1939, ten years after work ceased at St. Mary's, a team of scientists at the Sir William Dunn School of Pathology at the University of Oxford, led by Howard Florey that included Edward Abraham, Ernst Chain, Norman Heatley and Margaret Jennings, began researching penicillin. Their starting point was Fleming's largely forgotten paper and a sample of penicillin mould Fleming had given to their laboratory in 1930. They developed a method for cultivating the mould and extracting, purifying and storing penicillin from it, together with an assay for measuring its purity. Chain hit upon the idea of freeze drying it, which enabled the water to be removed, resulting in a dry, brown powder. They carried out experiments with animals to determine penicillin's safety and effectiveness before conducting clinical trials and field tests. They derived its chemical structure and determined how it works. The private sector and the United States Department of Agriculture located and produced new strains and developed mass production techniques. During the Second World War penicillin became an important part of the Allied war effort, and is credited with saving the lives of thousands of soldiers.
== References == Blauw, H.; et al. (2020), "Clinical validation of a bihormonal artificial pancreas", Diabetes Technology & Therapeutics, vol. 22, Mary Ann Liebert, INC 140 Huguenot Street, 3RD FL, NEW ROCHELLE, NY 10801 USA, p. A36-A37
One of the first adoptions of the trope is Rachel Pollack's Tree House (1984). The titular megaflora in Larry Niven's 1984 novel The Integral Trees exist within an orbiting gaseous torus full of life adapted to free-fall. The concept is discussed in Carl Sagan and Ann Druyan's 1985 non-fiction book Comet, and several paintings of Dyson trees around Saturn and in interstellar space are provided in the book by Jon Lomberg. In Michael Swanwick's 1987 transhumanist novel Vacuum Flowers, "dysonsworlders" have established tree settlements in the Oort Cloud. Under the name of "Space Poplars", Dyson trees are described in Donald Moffitt's two science fiction novels, The Genesis Quest and Second Genesis. Here they are used as both habitats and spacecraft, propelled by reflective outer leaves used as organic solar sails. Dan Simmons, in Endymion (1996) and the Rise of Endymion (1997) – both part of his Hyperion Cantos – refers to Dyson trees, and in the latter novel to a huge tree system that surrounds an entire star (reminiscent of a Dyson sphere). In Stephen Baxter's Manifold: Space (2001), Baxter's protagonist Reid Malenfant at one point finds himself inside a Dyson tree. In the Orion's Arm shared universe (established 2000), Dyson trees and Dyson tree "forests" are called orwoods; these have been established in a number of star systems throughout terragen space. The word "Orwood" in this context was originally coined by Anders Sandberg. The Transhuman Space roleplaying game includes the beginning of a Dyson tree endeavour on Yggdrasil Station.
== Notable people == Eric Decker, National Football League player Alvin Ganzer (1911–2009), film director, born in Cold Spring John J. Kinzer (1891–1986), Minnesota state legislator and farmer Doug Stang, Minnesota state legislator Justin Stommes, professional basketball player; graduated from Rocori High School
He returned in round 7, but had a subsequent dip in form. However, Essendon coach, Matthew Knights, persisted with Jetta and was paid back by his outstanding performance against Fremantle in round 14. The 2009 season was another important year in Jetta's development. A few quiet performances in the pre-season led to his omission from the side for the opening two rounds of the season. However, strong form for the Bendigo Bombers led to a recall for Essendon's vital round 3 encounter with Carlton. On 7 September 2014, Jetta parted ways with Essendon after eight seasons with the club. Jetta, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in February 2017; as a result, he served approximately seventeen months of his suspension and missed the entire 2016 WAFL season and parts of the 2015/16 and 2016/17 NTFL seasons. He later played with Peel Thunder in the WAFL and played for Pinjarra in the WA Amateur Football League in 2018.
Sources: en.wikipedia.org
== Industrial production and stability == Large‑scale vitamin A manufacture couples a C15 β‑ionone fragment with a C5 acetate side chain via a series of Wittig‑Horner and Grignard reactions, followed by final esterification or trans‑esterification to retinyl acetate. Modern processes achieve >95 % all‑trans selectivity and include crystallization or column purification under nitrogen to minimize isomerization.
Postmenopausal osteoporosis Hypercalcaemia Bone metastases Paget's disease Phantom limb pain It has been investigated as a possible non-operative treatment for spinal stenosis. The following information is from the UK Electronic Medicines Compendium
=== Seizures === For drug-resistant focal epilepsy, pregabalin is useful as an add-on therapy to other treatments. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use.
=== Active site === In addition to the Schiff base linkage, PLP is anchored to the active site of the enzyme via hydrogen bonding at the Tyr 207 and Glu237 residues. In addition, the phosphate oxygen atoms on the PLP molecule interact with the Arg99, Val269, Val270, and Thr310 residues. Mammalian BCATs show a unique structural CXXC motif (Cys315 and Cys318) sensitive to oxidizing agents and modulated through S-nitrosation, a post-translational modification that regulates cell signaling. Modification of these two cysteine residues via oxidation (in vivo/vitro) or titration (in vitro) has been found to inhibit enzyme activity, indicating that the CXXC motif is crucial to optimal protein folding and function. The sensitivity of both isoenzymes to oxidation make them potential biomarkers for the redox environment within the cell. Although the CXXC motif is present only in mammalian BCATs, the surrounding amino acid residues were found to be highly conserved in both prokaryotic and eukaryotic cells. Conway, Yeenawar et al. found that the mammalian active site contains three surfaces: surface A (Phe75, Tyr207 and Thr240), surface B (Phe30, Tyr141, and Ala314), and surface C (Tyr70, Leu153 and Val155, located on the opposite domain) that bind to the substrate in a Van der Waals-type interaction with the branched side chains of the amino acid substrates.
Repeated drug exposure changes how genes are switched on and off in the brain's reward circuits without altering the underlying DNA sequence, a set of processes known as epigenetic regulation. Three kinds of change have been implicated: chemical modification of the histone proteins around which DNA is wound, methylation of the DNA itself, and altered levels of small regulatory molecules called microRNAs. In rodents, some drug-induced epigenetic marks can be passed from parent to offspring and alter the offspring's response to the same drug, in some experiments reducing rather than increasing their drug taking. Neither the inheritance of these marks in humans nor their behavioral effects has been established.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.